Summary & Overview
HCPCS C9172: Injection of Fidanacogene Elaparvovec-dzkt, Therapeutic Dose
HCPCS Level II code C9172 denotes the injection of fidanacogene elaparvovec-dzkt, billed per therapeutic dose. This code captures administration of a gene therapy product delivered by injection and is significant as gene therapies become more common in specialty care. Nationally, accurate coding for high-cost, single-dose biologics and gene therapies affects coverage determinations, prior authorization pathways, and hospital billing workflows.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what C9172 represents clinically and operationally, an overview of typical sites of service, and what to expect in payer coverage considerations for high-cost injectable gene therapies. The report summarizes benchmarks where available, highlights recent policy developments affecting billing and coverage of novel therapeutics, and provides clinical context about service delivery and billing implications.
This summary is intended for revenue cycle managers, coding specialists, and policy analysts seeking a national-level briefing on billing and policy issues related to injectable gene therapy administration under HCPCS Level II code C9172.
Billing Code Overview
HCPCS Level II code C9172 describes the injection of fidanacogene elaparvovec-dzkt, per therapeutic dose. This code represents a billed administration of a gene therapy product delivered as an injected therapeutic dose. The service type is an injectable gene therapy administration. The typical site of service for this therapy is an ambulatory infusion or specialty clinic setting, including hospital outpatient departments or authorized specialty treatment centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with severe hemophilia B with inhibitory antibodies or a genetic variant qualifying for gene therapy who presents to a tertiary care infusion center or hospital outpatient clinic for a one-time administration of fidanacogene elaparvovec-dzkt. Pre-procedure workflow includes multidisciplinary evaluation by hematology, baseline laboratory testing (including factor IX activity, viral serologies, liver function tests), informed consent, and review of prior gene therapy eligibility criteria. On the day of service the patient undergoes enrollment verification and payer preauthorization. The therapeutic dose, supplied by pharmacy as a single-use vial or dose bag, is prepared under aseptic technique in an operating room or ambulatory infusion suite. Administration is by intravenous infusion or vector-specific delivery per product instructions, with continuous monitoring for infusion reactions and hemodynamic stability. Post-infusion observation typically occurs in the outpatient recovery area or hospital observation unit for several hours to days depending on clinical status and payer requirements. Follow-up visits with hematology and laboratory monitoring (including liver enzymes and factor IX activity) are scheduled at regular intervals post-procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typically required for the procedure (document rationale). |